MedTrace Logo

Assessment of MGMT Promoter Methylation in Advanced Ewing Sarcoma Treated With Temozolomide and Irinotecan

NCT03542097 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 82

Last updated 2023-05-15

No results posted yet for this study

Summary

This is a biological study in patients with advanced Ewing Sarcoma who received, according, clinical practice, temozolomide and irinotecan The O6-methylguanine-DNA methyltransferase (MGMT) methylation status, will be correlated with the disease clinical data and with the disease response

Conditions

  • Ewing Sarcoma Family of Tumors

Interventions

OTHER

MGMT methylation evaluation

The MGMT methylation will be evaluated by extracting DNA from fresh and Formalin Fixed paraffin Embedded (FFPE) tumor samples

Sponsors & Collaborators

  • Regione Emilia-Romagna

    collaborator OTHER

  • Istituto Ortopedico Rizzoli

    lead OTHER

Principal Investigators

  • Emanuela Palmerini, MD · Rizzoli Orthopedic Institute

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-15
Primary Completion
2018-12-31
Completion
2019-06-30

Countries

  • Italy
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03542097 on ClinicalTrials.gov